124 related articles for article (PubMed ID: 38368947)
1. Engineering stable and non-immunogenic immunoenzymes for cancer therapy via in situ generated prodrugs.
Tseng YH; Lin HP; Lin SY; Chen BM; Vo TNN; Yang SH; Lin YC; Prijovic Z; Czosseck A; Leu YL; Roffler SR
J Control Release; 2024 May; 369():179-198. PubMed ID: 38368947
[TBL] [Abstract][Full Text] [Related]
2. Local enzymatic hydrolysis of an endogenously generated metabolite can enhance CPT-11 anticancer efficacy.
Prijovich ZM; Chen KC; Roffler SR
Mol Cancer Ther; 2009 Apr; 8(4):940-6. PubMed ID: 19372567
[TBL] [Abstract][Full Text] [Related]
3. Impediments to enhancement of CPT-11 anticancer activity by E. coli directed beta-glucuronidase therapy.
Hsieh YT; Chen KC; Cheng CM; Cheng TL; Tao MH; Roffler SR
PLoS One; 2015; 10(2):e0118028. PubMed ID: 25688562
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of CPT-11 antitumor activity by adenovirus-mediated expression of β-glucuronidase in tumors.
Huang PT; Chen KC; Prijovich ZM; Cheng TL; Leu YL; Roffler SR
Cancer Gene Ther; 2011 Jun; 18(6):381-9. PubMed ID: 21350582
[TBL] [Abstract][Full Text] [Related]
5. A humanized immunoenzyme with enhanced activity for glucuronide prodrug activation in the tumor microenvironment.
Chen KC; Wu SY; Leu YL; Prijovich ZM; Chen BM; Wang HE; Cheng TL; Roffler SR
Bioconjug Chem; 2011 May; 22(5):938-48. PubMed ID: 21443266
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats.
Takasuna K; Hagiwara T; Hirohashi M; Kato M; Nomura M; Nagai E; Yokoi T; Kamataki T
Cancer Chemother Pharmacol; 1998; 42(4):280-6. PubMed ID: 9744772
[TBL] [Abstract][Full Text] [Related]
7. Enhancing SN38 prodrug delivery using a self-immolative linker and endogenous albumin transport.
Jiang X; Zhu L; Wei Q; Lu W; Yu J; Zhu S
J Control Release; 2024 May; 369():622-629. PubMed ID: 38604383
[TBL] [Abstract][Full Text] [Related]
8. Human neural stem cell tropism to metastatic breast cancer.
Zhao D; Najbauer J; Annala AJ; Garcia E; Metz MZ; Gutova M; Polewski MD; Gilchrist M; Glackin CA; Kim SU; Aboody KS
Stem Cells; 2012 Feb; 30(2):314-25. PubMed ID: 22084033
[TBL] [Abstract][Full Text] [Related]
9. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker.
Conover CD; Greenwald RB; Pendri A; Gilbert CW; Shum KL
Cancer Chemother Pharmacol; 1998; 42(5):407-14. PubMed ID: 9771956
[TBL] [Abstract][Full Text] [Related]
10. The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model.
Dodds HM; Tobin PJ; Stewart CF; Cheshire P; Hanna S; Houghton P; Rivory LP
J Pharmacol Exp Ther; 2002 Nov; 303(2):649-55. PubMed ID: 12388647
[TBL] [Abstract][Full Text] [Related]
11. The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours.
Tobin P; Clarke S; Seale JP; Lee S; Solomon M; Aulds S; Crawford M; Gallagher J; Eyers T; Rivory L
Br J Clin Pharmacol; 2006 Jul; 62(1):122-9. PubMed ID: 16842384
[TBL] [Abstract][Full Text] [Related]
12. Structural Optimization and Enhanced Prodrug-Mediated Delivery Overcomes Camptothecin Resistance in High-Risk Solid Tumors.
Nguyen F; Guan P; Guerrero DT; Kolla V; Naraparaju K; Perry LM; Soberman D; Pressly BB; Alferiev IS; Chorny M; Brodeur GM
Cancer Res; 2020 Oct; 80(19):4258-4265. PubMed ID: 32839252
[TBL] [Abstract][Full Text] [Related]
13. Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen.
Kurita A; Kado S; Matsumoto T; Asakawa N; Kaneda N; Kato I; Uchida K; Onoue M; Yokokura T
Cancer Chemother Pharmacol; 2011 Jan; 67(1):201-13. PubMed ID: 20354702
[TBL] [Abstract][Full Text] [Related]
14. Intravenous administration of irinotecan elevates the blood beta-glucuronidase activity in rats.
Kaneda N; Kurita A; Hosokawa Y; Yokokura T; Awazu S
Cancer Res; 1997 Dec; 57(23):5305-8. PubMed ID: 9393754
[TBL] [Abstract][Full Text] [Related]
15. The relative contributions of carboxylesterase and beta-glucuronidase in the formation of SN-38 in human colorectal tumours.
Tobin PJ; Dodds HM; Clarke S; Schnitzler M; Rivory LP
Oncol Rep; 2003; 10(6):1977-9. PubMed ID: 14534729
[TBL] [Abstract][Full Text] [Related]
16. Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue.
Chen KC; Schmuck K; Tietze LF; Roffler SR
Mol Pharm; 2013 May; 10(5):1773-82. PubMed ID: 23448264
[TBL] [Abstract][Full Text] [Related]
17. Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors.
Hattori Y; Shi L; Ding W; Koga K; Kawano K; Hakoshima M; Maitani Y
J Control Release; 2009 May; 136(1):30-7. PubMed ID: 19331859
[TBL] [Abstract][Full Text] [Related]
18. Impact of obesity on accumulation of the toxic irinotecan metabolite, SN-38, in mice.
Mallick P; Shah P; Gandhi A; Ghose R
Life Sci; 2015 Oct; 139():132-8. PubMed ID: 26334566
[TBL] [Abstract][Full Text] [Related]
19. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
Fukushima M; Sakamoto K; Ohshimo H; Nakagawa F; Taguchi T
Oncol Rep; 2010 Oct; 24(4):835-42. PubMed ID: 20811661
[TBL] [Abstract][Full Text] [Related]
20. Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan.
Rivory LP; Robert J
Cancer Chemother Pharmacol; 1995; 36(2):176-9. PubMed ID: 7767955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
